Zacks Research Analysts Reduce Earnings Estimates for PBH

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Equities researchers at Zacks Research reduced their Q3 2026 earnings per share estimates for shares of Prestige Consumer Healthcare in a note issued to investors on Thursday, October 16th. Zacks Research analyst Team now expects that the company will post earnings of $1.20 per share for the quarter, down from their previous forecast of $1.21. Zacks Research has a “Strong Sell” rating on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.50 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q4 2026 earnings at $1.37 EPS, FY2026 earnings at $4.50 EPS, Q4 2027 earnings at $1.25 EPS and FY2027 earnings at $4.81 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last announced its earnings results on Thursday, August 7th. The company reported $0.95 earnings per share for the quarter, missing the consensus estimate of $1.01 by ($0.06). Prestige Consumer Healthcare had a return on equity of 12.69% and a net margin of 19.02%.The business had revenue of $249.53 million for the quarter, compared to analysts’ expectations of $260.71 million. During the same quarter last year, the firm earned $0.90 earnings per share. The firm’s quarterly revenue was down 6.6% compared to the same quarter last year. Prestige Consumer Healthcare has set its FY 2026 guidance at 4.500-4.580 EPS.

PBH has been the topic of several other reports. Weiss Ratings restated a “hold (c)” rating on shares of Prestige Consumer Healthcare in a research note on Wednesday, October 8th. Sidoti upgraded Prestige Consumer Healthcare from a “neutral” rating to a “buy” rating and set a $80.00 target price on the stock in a research note on Wednesday, September 24th. Wall Street Zen cut Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Saturday, August 9th. Finally, Canaccord Genuity Group lowered their price target on Prestige Consumer Healthcare from $105.00 to $100.00 and set a “buy” rating for the company in a research report on Friday, August 8th. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $94.80.

Prestige Consumer Healthcare Stock Up 0.4%

Shares of PBH stock opened at $62.08 on Friday. Prestige Consumer Healthcare has a 1-year low of $60.15 and a 1-year high of $90.04. The stock’s fifty day moving average price is $64.31 and its 200 day moving average price is $75.38. The company has a debt-to-equity ratio of 0.55, a current ratio of 4.38 and a quick ratio of 2.99. The company has a market cap of $3.05 billion, a price-to-earnings ratio of 14.57, a price-to-earnings-growth ratio of 1.95 and a beta of 0.44.

Institutional Trading of Prestige Consumer Healthcare

Hedge funds have recently modified their holdings of the stock. UMB Bank n.a. boosted its stake in shares of Prestige Consumer Healthcare by 81.8% in the second quarter. UMB Bank n.a. now owns 320 shares of the company’s stock worth $26,000 after buying an additional 144 shares during the last quarter. Caitong International Asset Management Co. Ltd boosted its stake in shares of Prestige Consumer Healthcare by 312.5% in the second quarter. Caitong International Asset Management Co. Ltd now owns 330 shares of the company’s stock worth $26,000 after buying an additional 250 shares during the last quarter. Maseco LLP purchased a new stake in shares of Prestige Consumer Healthcare in the second quarter worth about $27,000. Elevation Point Wealth Partners LLC purchased a new stake in shares of Prestige Consumer Healthcare in the second quarter worth about $46,000. Finally, First Horizon Advisors Inc. boosted its stake in shares of Prestige Consumer Healthcare by 294.1% in the second quarter. First Horizon Advisors Inc. now owns 599 shares of the company’s stock worth $48,000 after buying an additional 447 shares during the last quarter. Hedge funds and other institutional investors own 99.95% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.